Review of Cannabis sativa for Major Depressive Disorder offers no clinical efficacy data

Photo by HighBabe / Unsplash

Frontiers in Medicine Published May 19, 2026 Medically reviewed May 19, 2026 DOI ↗ By Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

Key Takeaway

Note that this review lacks reported efficacy or safety data for Cannabis sativa in Major Depressive Disorder.

This publication is a narrative review focused on the use of Cannabis sativa and its bioactive constituents for Major Depressive Disorder. The scope of the article addresses the potential role of this botanical product in managing depressive symptoms. However, the text explicitly states that the sample size, population characteristics, and study setting were not reported. Similarly, no specific primary or secondary outcomes were quantified within the provided data.

The review does not present pooled effect sizes or specific adverse event rates because these metrics were not reported in the source material. The authors acknowledge that the tolerability profile and discontinuation rates remain unknown based on the available information. No specific funding sources or conflicts of interest were disclosed in the provided text.

Given the absence of reported numerical data and the observational nature of the synthesis, the practice relevance is limited. Clinicians should interpret these findings with caution as the evidence does not support definitive recommendations for clinical management of Major Depressive Disorder.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

Major Depressive Disorder (MDD) is a highly prevalent and disabling psychiatric disorder, representing a major global health burden across all age groups. Increasing evidence indicates that its pathophysiology involves a complex interplay between chronic stress, dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis, immune activation, and neuroinflammation. Persistent HPA axis hyperactivity, glucocorticoid resistance, and altered expression of key regulators such as FKBP51 contribute to sustained inflammatory signaling and impaired neural plasticity in brain regions involved in mood regulation. Epigenetic mechanisms, including DNA methylation and microRNA-mediated regulation, further modulate stress responsivity, inflammatory pathways, and vulnerability to major depressive disorder. In this context, growing attention has been directed toward Cannabis sativa and its bioactive constituents as potential therapeutic agents. Preclinical and clinical evidence suggest that cannabinoids may modulate the endocannabinoid system, attenuate HPA axis hyperactivity, reduce neuroinflammation, and influence monoaminergic and neuroplasticity-related pathways. This review synthesizes the current literature on the mechanistic links among the HPA axis, inflammation, and MDD, highlighting the emerging role of Cannabis sativa-derived compounds in targeting these interconnected pathways.